 
 
 
 
 
 
 
 
November 14, 2025 
 
BSE Limited        Code: 532321 
P J Towers, 
Dalal Street, 
Mumbai-400001 
 
National Stock Exchange of India Limited    Code: Zyduslife 
Exchange Plaza,  
C/1, Block G, 
Bandra-Kurla Complex, Bandra (East), 
Mumbai-400051 
 
Re.: Press Release 
 
Dear Sir / Madam, 
 
Please find enclosed a copy of press release dated November 14, 2025, titled “Zydus 
receives final approval from USFDA for Leuprolide Acetate injection, 14 mg/2.8 mL  
(1 mg/0.2 mL) multiple-dose vial”. 
 
The contents of the press release give full details. 
 
Please bring the aforesaid news to the notice of the members of the exchange and the 
investors’ at large. 
 
Yours faithfully, 
For, ZYDUS LIFESCIENCES LIMITED 
 
 
DHAVAL N. SONI 
COMPANY SECRETARY AND COMPLIANCE OFFICER 
MEMBERSHIP NO. FCS7063 
 
Encl.: As above 
 
 
 
 
 
 
 
Zydus receives final approval from USFDA for Leuprolide Acetate injection, 14 mg/2.8 
mL (1 mg/0.2 mL) multiple-dose vial 
 
Ahmedabad, India, 14 November, 2025  
 
Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as “Zydus”) has 
received final approval from the United States Food and Drug Administration (USFDA) for Leuprolide 
Acetate injection, 14 mg/2.8 mL (1 mg/0.2 mL) multiple-dose vial (USRLD: Lupron Injection®, 1 mg/0.2 
mL). 
 
Leuprolide Acetate injection is indicated in the palliative treatment of advanced prostatic cancer. 
Leuprolide Acetate injections will be manufactured at the Company’s oncology injectable manufacturing 
facility at SEZ1, Ahmedabad (‘ALIDAC’).  
 
Leuprolide Acetate injection had annual sales of USD 69 mn in the United States (IQVIA MAT Sept-
2025). 
 
The group now has 427 approvals and has so far filed 487* ANDAs since the commencement of the filing 
process in FY 2003-04. 
  
(*As on 30-Sept-25) 
 
 
 
